Tandem Diabetes Care (TNDM.O) shares trading around the flat line premarket after securing more capital than planned
San Diego, California-based insulin delivery systems manufacturer early Weds
private offering of $265 mln 0% 6-yr convertible bonds
Initial conversion price of $36.99 is 37.5% premium over stock’s last close of $26.90 TNDM shares fell 4.8% on Tues after co late Mon unveiled $200 mln offering for general purposes, including acquisitions or strategic investments, among other uses
Co to use $13.5 mln of proceeds to pay cost of capped calls; initial cap price set at $47.08, 75% above stock’s last close Through Tues, TNDM shares up 45% since co posted Q4 sales and adj operating income above LSEG estimates
Stock up 22% YTD as of last close after 39% drop in 2025
Avg rating of 24 analysts is “buy”; median PT $26, per LSEG data (Lance Tupper is a Reuters market analyst. The views expressed are his own)

SBIO

TNDM

Reuters

ALPS Medical Breakthrough

SPDR S&P Health Equip

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Medical Devices

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Tandem Diabetes

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

BUZZ-Tandem Diabetes steadies after boosted $265 mln convertible bonds sale